课题基金 / 基金详情

Non-viral genome, epigenome, and transcriptome engineering for clinical CAR-T cell manufacturing

Non-viral genome, epigenome, and transcriptome engineering for clinical CAR-T cell manufacturing
用于临床 CAR-T 细胞制造的非病毒基因组、表观基因组和转录组工程
批准号:
10696193
负责人:
Brian R Shy
金额:
$26.39万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-02 至 2027-08-31
关键词:
AchievementAdenosineAffectAllogenicAwardCAR T cell therapyCD47 geneCRISPR-mediated transcriptional activationCRISPR/Cas technologyCaliforniaCancer PatientCell ReprogrammingCell TherapyCell physiologyClinicalClinical EngineeringClinical Trials DesignClustered Regularly Interspaced Short Palindromic RepeatsCytosineDNADNA Repair PathwayDevelopmentEducational workshopEngineeringEpigenetic ProcessFDA approvedFosteringFundingGenesGeneticGenomeGoalsGood Manufacturing ProcessGrantHematologic NeoplasmsHumanHybridsImmuneImmunophenotypingKnock-inKnock-outKnowledgeLaboratoriesLeadLibrariesMalignant NeoplasmsMediatingMediatorMentorsMethodsModalityModificationMultiple MyelomaNonhomologous DNA End JoiningNuclearNucleotidesOutcomePathogenicityPathway interactionsPatientsPhysiciansPhysiologicalProcessProductionRegulatory ElementResearchResearch ActivityResearch PersonnelResearch ProposalsRoleSafetySan FranciscoScientistSingle-Stranded DNASiteSourceT cell therapyT-Cell ReceptorT-LymphocyteTechnologyTherapeuticToxic effectTrainingTreatment outcomeUniversitiesViralViral VectorVirusWritingbase editingbase editorcancer therapycareercareer developmentcellular engineeringchimeric antigen receptorchimeric antigen receptor T cellsclinical implementationclinical trainingcostcurative treatmentsengineered T cellsepigenomegenetic elementhuman diseaseimprovedlarge datasetsmanufacturemanufacturing processmeetingsnext generationnext generation sequencingnovelpreclinical developmentpreclinical studyprogramsrepairedresponseskillssmall moleculesmall molecule inhibitorstandard of caresymposiumtooltranscriptometransfusion medicine

项目摘要

项目成果

Brian R Shy的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT The goal of this application is to train Dr. Brian Shy, a physician scientist at the University of California San Francisco, with the skills necessary to become an independently-funded investigator studying, developing, and manufacturing engineered cellular therapies. This research proposal will evaluate CRISPR-based non-viral methods for targeted genome, epigenome, and transcriptome engineering in primary human T cells. This will be applied to understand DNA repair pathway choice and DNA toxicity responses in order to improve site-specific “knock-in” strategies with large therapeutic constructs such as chimeric antigen receptors (CARs), develop safe and efficient methods for multiplexed T cell modifications, and establish Good Manufacturing Practice (GMP) compatible processes for clinical implementation of this diverse toolset. This research is accompanied by a career development and training plan that will build on Dr. Shy's clinical training in Transfusion Medicine and Cellular Therapy, and his prior expertise in the pre-clinical development and manufacturing of experimental cellular therapies. Training will focus on 1) implementation of novel cellular engineering tools, 2) next generation sequencing (NGS) technologies and analysis of large datasets, 3) GMP manufacturing and pre-clinical development, 4) clinical trial design and standard-of-care cellular therapies, and 5) laboratory management, grant writing, presentation, and research strategy skills. This career development and training plan will include a combination of formal coursework, mentored practical training; conference, meeting, and workshop attendance; and guidance from an exceptional team of co-mentors, advisors, and collaborators. Altogether, this award will help prepare Dr. Shy for an independent research career focused on developing improved cellular therapies for treatment of cancer and other human diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Non-viral genome, epigenome, and transcriptome engineering for clinical CAR-T cell manufacturing
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
  • 批准号:
    82074359
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    安晓飞
  • 依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制